Novo Nordisk Wegovy 7.2mg Achieves 21% Loss

Novo Nordisk presented STEP UP trial data at Congress on Obesity, Istanbul, showing 7.2 mg Wegovy leads to 21% weight loss over 72 weeks.
The 7.2 mg dose produced average 23 kg loss for a 113 kg baseline participant, outperforming the 2.4 mg dose (17.5%) and placebo (2.4%).
Early responders (≥15% loss) were 27% of the 7.2 mg group, losing 27.7% by week 72 versus 21% and 3% for 2.4 mg and placebo.
Fat mass accounted for 84% of weight loss, with >30% visceral fat reduction and only 10% muscle loss, preserving functional strength.